NVS Relative Valuation
NVS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVS is overvalued; if below, it's undervalued.
Historical Valuation
Novartis AG (NVS) is now in the Undervalued zone, suggesting that its current forward PE ratio of 12.92 is considered Undervalued compared with the five-year average of 13.76. The fair price of Novartis AG (NVS) is between 138.57 to 159.06 according to relative valuation methord. Compared to the current price of 112.75 USD , Novartis AG is Undervalued By 18.63%.
Relative Value
Fair Zone
138.57-159.06
Current Price：112.75
18.63%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
5.57
P/B
Median3y
4.29
Median5y
3.98
8.24
FCF Yield
Median3y
6.91
Median5y
6.77
Competitors Valuation Multiple
The average P/S ratio for NVS's competitors is 4.39, providing a benchmark for relative valuation. Novartis AG Corp (NVS) exhibits a P/S ratio of 4.01, which is -8.84% above the industry average. Given its robust revenue growth of 12.67%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Novartis AG (NVS) currently overvalued or undervalued?
What is Novartis AG (NVS) fair value?
How does NVS's valuation metrics compare to the industry average?
What is the current P/B ratio for Novartis AG (NVS) as of May 24 2025?
What is the current FCF Yield for Novartis AG (NVS) as of May 24 2025?
What is the current Forward P/E ratio for Novartis AG (NVS) as of May 24 2025?